PennyOmega.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From PennyOmega.com

________________________________________

 

Monday August 31, 2009

PennyOmega.com Stock Report!

**************************************************************

The Lockheed Martin (NYSE: LMT) -led Next Generation Identification (NGI) team has successfully completed Critical Design Review (CDR) for the system’s fingerprint identification capability, clearing the way for further progress on the Federal Bureau of Investigation’s (FBI) new multi-modal, state-of-the-art biometrics system.

Guidance Software Inc. (NASDAQ:GUID), The World Leader in

...

QuantRx Biomedical Corp. is a diagnostics company engaged in the development and commercialization of innovative diagnostic products centered on its patented technology platforms. Friday, the company announced its joint venture with NuRx Pharmaceuticals Inc. (NUXP.OB), a life sciences company engaged in the research and development of oncology products and relative care.

The joint venture was formed to accelerate efforts to take advantage of Point-of-Care (POC) products. Per the agreement, NuRx will provide the new venture, QN Diagnostics LLC, with more than $5 million of working capital, which will be used for marketing and revenue generation of its POC line of products.

Equally owned by QuantRx and NuRx, QN Diagnostics is supported by 30 years of diagnostic healthcare research and development expertise, and will move the companies forward in the market. “The formation of QN Diagnostics is an extraordinary milestone for QuantRx, its shareholders and the global healthcare community,” Walter Witoshkin,

...

Fiscal 2009 third quarter financial performance remains strong Myriad Genetics, Inc. (MYGN) relies on its molecular diagnostic products for its revenue generation and is currently seeing solid growth in this business. On May 4, 2009, the company reported fiscal 3Q09 financial results ended March 31, 2009.Total revenue for the 2009 fiscal third quarter increased to a record $87.5 million, compared with $61.8 million in the prior-year period. Molecular diagnostic revenues rose 47% to $86.5 million from $59.0 million last year. The improvement resulted primarily from an increase in the Company's sales and marketing efforts, including expansion of its women's health sales force. It was also due to the continuation of its direct-to-consumer marketing campaign, which the company believes has resulted in improved physician acceptance and adoption of its molecular diagnostic products. Molecular diagnostic revenue of $86.5 million in 3Q09 was slightly lower than our ...

Buy Rating Maintained for Myriad Genetics in Anticipation of Another Strong Quarter We maintain our Buy rating for Myriad Genetics (MYGN) in anticipation of strong fiscal third quarter performance ending March 31, 2009. We also raise our price target to $53 from original $50 based on recent recommendation by the American College of Obstetricians and Gynecologists (ACOG) that routine screening for Hereditary Breast and Ovarian Cancer should performed. The new price target also reflects the two for one stock split effective on March 25, 2009.  Myriad Genetics will report its fiscal third quarter results early next month. We maintain our optimism on the predictive medicine and believe this business will keep recording double-digit growth in the coming years. Revenue will grow at a CAGR of 31% during the 2009-2012 periods while EPS will maintain a CAGR of 39% during the 2009-2012 periods....